Lille hosted the 2024 editions of BioFIT, MedFIT, and MEDigIT, three internationally recognised events dedicated to innovation in Life Sciences, MedTech and Digital Health. These gatherings serve as catalysts for collaboration and progress, each focusing on a specific aspect of the healthcare innovation landscape.
Project Eaden bags €15m to scale up production
Latest NewsBerlin-based food tech start-up Project Eaden is prepared to launch its first plant-based ham product by mid-year in 2,000 REWE supermarkets. A oversubscribes Series A financing laid the basis for this success
Ceres Brain Therapeutics announces €6m financing
Latest NewsParis-based drug delivery specialist Ceres Brain Therapeutics SA has raised €6m led by ANJAC, a French family-owned industrial group and preferred partner of healthcare laboratories and beauty and well-being brands, to support the clinical development neurological treatments.
Medix Biochemica acquires CANDOR Bioscience
Sponsored PublicationsMedix Biochemica Expands its Offering of Critical IVD Raw Materials to Premium Blockers and Stabilizers by Acquiring CANDOR Bioscience.
Arctic Therapeutics ASA kicks off with €26.5m Series A round
Latest NewsIceland’s Arctic Therapeutics has secured €26.5m in a Series A financing aimed to push its oral drug candidates AT-O01 and AT-004 into clinical trails in patients with rare amyloid aggregation diseases including Alzheimer’s disease.
EuropaBio calling for EU Biotech Act
Latest NewsEuropaBio calls for an ambitious cross-sectoral EU Biotech Act, that strengthens Europe as a global biotechnology leader for competitiveness and strategic autonomy.
PRAC: Semaglutide linked to rare eye disease?
Latest NewsThe Safety Committee PRAC of the European Medicines Agency EMA is investigating a new potential adverse reaction to the appetite suppressant semaglutide. Epidemiological studies indicate that the rare eye disease non-arteritic anterior ischaemic optic neuropathy (NAION), which leads to blindness, could occur more frequently after treatment with the GLP-1 receptor agonist.
2024 BioFIT, MedFIT and MEDigIT editions: Fostering innovation and excellence in the healthcare sector
Sponsored PublicationsLille hosted the 2024 editions of BioFIT, MedFIT, and MEDigIT, three internationally recognised events dedicated to innovation in Life Sciences, MedTech and Digital Health. These gatherings serve as catalysts for collaboration and progress, each focusing on a specific aspect of the healthcare innovation landscape.
InflaRx secures European Commission approval for ARDS drug
Latest NewsJena-based InflaRx has reached a significant milestone with the European Commission’s approval of GOHIBIC (Vilobelimab), a novel anti-C5a monoclonal antibody for the treatment of SARS-CoV-2-induced Acute Respiratory Distress Syndrome (ARDS).
Synairgen raises £18m for Phase 2 INVENT trial of SNG001
Latest NewsSynairgen plc (SNG) has announced the successful completion of a £18m funding round, primarily supported by TFG Asset Management. The funding will advance the Phase 2 INVENT trial, assessing SNG001, an inhaled formulation of the antiviral protein interferon beta, in mechanically ventilated patients with severe viral lung infections.
Johnson & Johnson acquires Intra-Cellular Therapies for $14.6 billion
Latest NewsJohnson & Johnson has announced the acquisition of biopharmaceutical company Intra-Cellular Therapies, strengthening its position in the market for central nervous system disorder treatments. The $14.6 billion deal involves J&J paying $132 per share, representing a 39% premium over Intra-Cellular’s last closing price.